PRRT in Hindgut and Cancer of Unknown Primary NEN Abstract #2290

Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).
Aim(s): To compare the long term effectiveness of PRRT (90Y or 177Lu DOTATATE), based on OS and PFS, in patients with extensive, progressive, non-resectable NEN hindgut and CUP origin.
Materials and methods: 22 patients, hindgut, n=8 and CUP n=14. All treated with PRRT; 177Lu (n=8); 90Y (n=14). Clinical responses were assessed 6 weeks after PRRT and then at the 3-month intervals. The clinical efficacy determine evaluating performance status (PS) and reduction of clinical symptoms. OS and PFS were assessed using Kaplan –Meier. Radiological response was classified according to RECIST 1.0.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD, PhD Agnieszka Kolasińska-Ćwikła
Keywords: NENs, PRRT, Hindgut, CUP

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2060 Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity
Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Theodora Liotsou
Keywords: NENs, PRRT
#3039 Evaluation of Overall Survival (OS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)
Introduction: In many cases, the cause of death in patients with carcinoid syndrome (CS) is carcinoid heart disease (CHD) which is most often diagnosed in patients with SI-NEN.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: Sonia Konsek-Komorowska
#1568 Neuroendocrine Neoplasm of the Colon and Rectum, Pathological and Clinical Characteristics, Based on pTNM WHO 2010 Classification
Introduction: Large bowel neuroendocrine neoplasms (NENs)
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Jaroslaw Cwikła
#1894 Survival Analysis after i.a. 90Y-DOTATATE PRRT, in Patients with Non-Resectable, Advanced, Progressive, Liver-Dominant Neuroendocrine Neoplasms
Introduction: A
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: MD, PhD Miroslaw L Nowicki
#2268 Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)
Introduction: SSA are the first line therapy in well differentiated pNET
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Md, PhD Agnieszka Kolasińska-Ćwikla